In this study, we revealed that GBP1–5 are significantly downregulated in AML, ALL, or CLL patients compared with the non-leukemic population (Fig. 6a), and elevated levels of GBP1, GBP3, GBP4, and GBP6 are associated with prolonged survival time in leukemia and lymphoma patients (Fig. 6c). This evidence concerns the gene GBP3 and leukemia.